Correction to: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure.

MLA

Lim, Soo Kun, et al. “Correction to: A Multicentre, Multi-National, Double-Blind, Randomised, Active-Controlled, Parallel-Group Clinical Study to Assess the Safety and Efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in Patients with Anaemia of Chronic Renal Failure.” BMC Nephrology, vol. 23, no. 1, Jan. 2022, p. 14. EBSCOhost, https://doi.org/10.1186/s12882-021-02651-0.

APA

Lim, S. K., Goh, B. L., Visvanathan, R., Kim, S. H., Jeon, J. S., Kim, S. G., Chang, J. H., Lim, C. S., & Morad, Z. (2022). Correction to: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure. BMC Nephrology, 23(1), 14. https://doi.org/10.1186/s12882-021-02651-0

Chicago

Lim, Soo Kun, Bak Leong Goh, Ravindran Visvanathan, Su Hyun Kim, Jin Seok Jeon, Sung Gyun Kim, Jae Hyun Chang, Chun Soo Lim, and Zaki Morad. 2022. “Correction to: A Multicentre, Multi-National, Double-Blind, Randomised, Active-Controlled, Parallel-Group Clinical Study to Assess the Safety and Efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in Patients with Anaemia of Chronic Renal Failure.” BMC Nephrology 23 (1): 14. doi:10.1186/s12882-021-02651-0.